Novo Nordisk (NVO) said Wednesday its US operations will no longer take part in a global initiative on gender representation because of "evolving legal requirements."
The company said that worldwide, it continues to work to achieve representation of at least 45% for each gender by the end of this year.
"We remain committed to non-discrimination and innovation through diverse perspectives, always in compliance with local regulations," the Danish drugmaker said in its Q1 earnings release.
Price: 68.68, Change: +2.39, Percent Change: +3.61
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.